ChiCTR2000031857 版本V1.2 版本创建时间2020/04/12 17:49:28 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000031857 

最近更新日期:

Date of Last Refreshed on:

2020-04-12 17:34:42 

注册时间:

Date of Registration:

1990-01-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

经皮左心耳封堵的最佳麻醉方法

Public title:

Optimal Anesthetic Methods For Percutaneous Left Atrial Appendage Closure

注册题目简写:

English Acronym:

研究课题的正式科学名称:

麻醉学

Scientific title:

Anesthesiology

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李琼珍 

研究负责人:

吴镜湘 

Applicant:

Qiongzhen- Li 

Study leader:

Jingxiang Wu 

申请注册联系人电话:

Applicant telephone:

18917129132

研究负责人电话:

Study leader's
telephone:

18019370636

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

475166534@qq.com

研究负责人电子邮件:

Study leader's E-mail:

Wu_jingxiang@shchest.org

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市胸科医院麻醉科

研究负责人通讯地址:

上海市胸科医院麻醉科

Applicant address:

Department of Anesthesiology of ShangHai chest Hospital

Study leader's address:

Department of Anesthesiology of ShangHai chest Hospital

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海市胸科医院

Applicant's institution:

ShangHai chest Hospital

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KS1864

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海交通大学附属上海市胸科医院伦理委员会

Name of the ethic committee:

the Institutional Review Board of Shanghai Jiaotong University ShangHai chest hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2018-08-28 00:00:00

伦理委员会联系人:

徐美英

Contact Name of the ethic committee:

上海交通大学附属上海市胸科医院伦理委员会

伦理委员会联系地址:

徐汇区淮海西路241号

Contact Address of the ethic committee:

Huaihai West Road 241#,Xuhui,Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市胸科医院

Primary sponsor:

ShangHai chest Hospital

研究实施负责(组长)单位地址:

上海市胸科医院

Primary sponsor's address:

ShangHai chest Hospital

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市胸科医院

具体地址:

徐汇区淮海西路241号

Institution
hospital:

ShangHai Chest Hospital

Address:

241 Huaihai Road West, Xuhui District

经费或物资来源:

上海市胸科医院

Source(s) of funding:

ShangHai chest Hospital

研究疾病:

心脏病  

Target disease:

heart disease

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

探讨经皮左心耳封堵的最佳麻醉方法  

Objectives of Study:

Explore the best anesthesia method for percutaneous occlusion of left atrial appendage

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

ASA2-3级
接受经皮左心耳封堵术
气管插管全身麻醉

Inclusion criteria

ASA2-3
The patients were were scheduled to percutaneous left atrial appendage closure surgery, and receiving endotracheal intubation general anesthesia with cisatracurium-neostigmine or rocuronium-sugammadex.

排除标准:

拒绝参加
精神类药物使用史
肝肾疾病史
新斯的明或阿托品过敏史
认知功能障碍
怀孕或哺乳期

Exclusion criteria:

the patients refused to participate,
use of psychiatric medications and alcohol abuse,
with a history of liver and kidney disease,
contraindication to neostigmine and/or atropine
or cognitive impairment or pregnant or lactating.

研究实施时间:

Study execute time:

From 2020-04-12 00:00:00 To 2020-06-12 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-04-12 00:00:00 To 2020-06-12 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

42

Group:

control group

Sample size:

干预措施:

丙泊酚-舒芬太尼-顺式阿曲库铵-新斯的明

干预措施代码:

Intervention:

propofol-sufentanil-cisatracurium-neostigmine

Intervention code:

组别:

试验组

样本量:

42

Group:

experimental group

Sample size:

干预措施:

丙泊酚-瑞芬太尼-罗库溴铵-布瑞亭

干预措施代码:

Intervention:

propofol-refentanil-rocuronium-sugammadex

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市胸科医院 

单位级别:

三甲 

Institution
hospital:

Shanghai Chest Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

苏醒质量

指标类型:

主要指标

Outcome:

the Quality of Recovery

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

项目负责人采用随机数字表将患者分为两组

Randomization Procedure (please state who generates the random number sequence and by what method):

The patients were randomly divided into two groups by the project leader useing a random number table.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

临床试验公共管理平台Resman

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

www.medresman.org

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表(Case Record Form, CRF)和电子采集

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form and electronic collection

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-04-12 17:34:42